Grantham, Mayo, Van Otterloo & Co (GMO)’s Cardlytics CDLX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-33,953	Closed	-$48.5M	–	850
2020 Q4	$48.5M	Sell	33,953 -12,630	-27%	-$13.5M	0.3%	56
2020 Q3	$32.9M	Buy	46,583 +5,405	+13%	+$3.93M	0.23%	61
2020 Q2	$28.8M	Sell	41,178 -39,622	-49%	-$22.9M	0.21%	65
2020 Q1	$28.2M	Buy	80,800 +29,100	+56%	+$20.6M	0.24%	69
2019 Q4	$32.5M	Buy	51,700 +11,700	+29%	+$5.72M	0.22%	76
2019 Q3	$13.4M	Hold	40,000	–	–	0.09%	152
2019 Q2	$10.4M	Buy	+40,000	New	+$8.01M	0.07%	187

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ACM

Alua Capital Management New York $103M AUM 11.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s CDLX Position: Q1 2021 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Cardlytics (CDLX) in Q1 2021, closing a stake of 33,953 shares — an estimated $48.5M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CDLX in Q2 2019 and held it in 7 quarters. The position peaked at $48.5M in Q4 2020. 204 funds tracked by Wall St. Rank hold CDLX as of Q1 2021.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Cardlytics position as of Q1 2021 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 33,953 Cardlytics shares in Q1 2021, an estimated $48.5M.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Cardlytics in Q2 2019 and held it in 7 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Cardlytics position peaked at $48.5M in Q4 2020.
204 funds tracked by Wall St. Rank held Cardlytics as of Q1 2021.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2021, filed 13 May 2021.